Literature DB >> 9804277

Activation of LA-N-2 cell phospholipase D by amyloid beta protein (25-35).

I N Singh1, G Sorrentino, J N Kanfer.   

Abstract

Amyloid beta protein is the major protein component of neuritic plaques found in the brain of Alzheimer's disease. The activation of phospholipase D by amyloid beta protein (25-35), quisqualate and phorbol 12, 13-dibutyrate was investigated in LA-N-2 cells by measuring phosphatidylethanol formation. The activation of phospholipase D by quisqualate and APP (25-35) was calcium-independent. The AbetaP (25-35) and quisqualate activation of phospholipase D appeared to be mediated through a pertussis toxin-sensitive GTP-binding protein. Phospholipase D activation by AbetaP (25-35), quisqualate and phorbol dibutyrate was not blunted by the protein kinase C inhibitors, staurosporine, H-7 and RO-31-8220. However, it was abolished by overnight exposure to phorbol dibutyrate. This activation of phospholipase D was prevented by the tyrosine kinase inhibitor, genistein but not by tyrophostin A. Several excitatory amino acid antagonists were tested for their ability to prevent the phospholipase D activation by quisqualate and AbetaP (25-35). Only NBQX was effective with an IC50 of 75 microM for AbetaP (25-35) and quisqualate. Activation of phospholipase D by AbetaP or quisqualate was absent in LA-N-2 cells previously desensitized by quisqualate or AbetaP (25-35), but the activation by phorbol dibutyrate was unaltered. The responsiveness to AbetaP and quisqualate in previously desensitized cells reappeared subsequent to a period of resensitization. The observations with the antagonist NBQX, and the desensitization and resensitization experiments, are consistent with a receptor occupancy mediated activation of phospholipase D by quisqualate and by AbetaP (25-35).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804277     DOI: 10.1023/a:1020731813973

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  51 in total

1.  Amyloid beta protein (25-35) stimulation of phospholipase C in LA-N-2 cells.

Authors:  I N Singh; G Sorrentino; J N Kanfer
Journal:  J Neurochem       Date:  1997-07       Impact factor: 5.372

2.  Effects of ion channel blockers and phorbol ester treatments on [3H]dopamine release and neurotensin facilitation of [3H]dopamine release from rat mesencephalic cells in primary culture.

Authors:  A Brouard; D Pelaprat; M Vial; A M Lhiaubet; W Rostène
Journal:  J Neurochem       Date:  1994-04       Impact factor: 5.372

3.  Fusogenic properties of the C-terminal domain of the Alzheimer beta-amyloid peptide.

Authors:  T Pillot; M Goethals; B Vanloo; C Talussot; R Brasseur; J Vandekerckhove; M Rosseneu; L Lins
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

4.  Mechanism of amyloid beta-peptide (1-42) toxicity in PC12 cells.

Authors:  M O Fagarasan; S Efthimiopoulos
Journal:  Mol Psychiatry       Date:  1996-11       Impact factor: 15.992

5.  Reductions in membrane proteins and lipids in basal ganglia of classic Alzheimer disease patients.

Authors:  C G Gottfries; B Jungbjer; I Karlsson; L Svennerholm
Journal:  Alzheimer Dis Assoc Disord       Date:  1996       Impact factor: 2.703

6.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

7.  Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients.

Authors:  J K Blusztajn; I Lopez Gonzalez-Coviella; M Logue; J H Growdon; R J Wurtman
Journal:  Brain Res       Date:  1990-12-17       Impact factor: 3.252

8.  Ca2+-dependent and Ca2+-independent protein kinase C changes in the brain of patients with Alzheimer's disease.

Authors:  H Matsushima; S Shimohama; M Chachin; T Taniguchi; J Kimura
Journal:  J Neurochem       Date:  1996-07       Impact factor: 5.372

9.  Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease.

Authors:  J W Pettegrew; K Panchalingam; J Moossy; J Martinez; G Rao; F Boller
Journal:  Arch Neurol       Date:  1988-10

10.  Amyloid beta protein (25-35) stimulation of phospholipases A, C and D activities of LA-N-2 cells.

Authors:  I N Singh; D G McCartney; J N Kanfer
Journal:  FEBS Lett       Date:  1995-05-29       Impact factor: 4.124

View more
  4 in total

Review 1.  Amyloid beta peptide membrane perturbation is the basis for its biological effects.

Authors:  J N Kanfer; G Sorrentino; D S Sitar
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

2.  Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits.

Authors:  Tiago Gil Oliveira; Robin B Chan; Huasong Tian; Mikael Laredo; Guanghou Shui; Agnieszka Staniszewski; Hong Zhang; Lili Wang; Tae-Wan Kim; Karen E Duff; Markus R Wenk; Ottavio Arancio; Gilbert Di Paolo
Journal:  J Neurosci       Date:  2010-12-08       Impact factor: 6.167

3.  Activation of phospholipases A2 and D of a human neuroblastoma cell line (LA-N-2) by N-dodecyl-L-lysine amide (compound 24), a putative G protein activator: characteristics of inhibition by (-)-nicotine.

Authors:  Byron M Garnham; Shirley Fitzpatrick-Wong; Walter Schunack; Bernd Nürnberg; Giuseppe Sorrentino; Fiona E Parkinson; Julian N Kanfer; Daniel S Sitar
Journal:  Neurochem Res       Date:  2002-12       Impact factor: 3.996

Review 4.  Mammalian phospholipase D: Function, and therapeutics.

Authors:  M I McDermott; Y Wang; M J O Wakelam; V A Bankaitis
Journal:  Prog Lipid Res       Date:  2019-12-09       Impact factor: 16.195

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.